Compare MDBH & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | GBIO |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 35.4M |
| IPO Year | 2023 | 2020 |
| Metric | MDBH | GBIO |
|---|---|---|
| Price | $3.65 | $5.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 11.0K | ★ 58.5K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | $1,250,398.00 | ★ $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.16 | $3.00 |
| 52 Week High | $7.98 | $14.59 |
| Indicator | MDBH | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 47.36 |
| Support Level | $3.30 | $5.14 |
| Resistance Level | $3.69 | $5.38 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 27.12 | 50.00 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.